<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752503</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-NAL-2014-76</org_study_id>
    <nct_id>NCT02752503</nct_id>
  </id_info>
  <brief_title>Nalmefene in Alcohol Dependence and Borderline Personality Disorder</brief_title>
  <official_title>Open-label Trial on Therapeutic Effect and Tolerability of Nalmefene in Subjects With Alcohol Use Disorder and Comorbid Borderline Personality Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitari General de Catalunya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <brief_summary>
    <textblock>
      The objective is to study the effectiveness of Nalmefene in decreasing alcohol intake in
      subjects with alcohol use disorder and comorbid BPD.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days of excessive alcohol intake</measure>
    <time_frame>2 months</time_frame>
    <description>Excessive alcohol intake: &gt;60 g in males; &gt;40 g in females</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily average intake (grams)</measure>
    <time_frame>2 months</time_frame>
    <description>Daily average intake (grams)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Borderline symptoms on the Borderline Symptom List - 23 (BSL-23)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Impression of the Clinic on the Clinical Impression - BPD (GCI-BPD)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>Nalmafene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalmefene</intervention_name>
    <arm_group_label>Nalmafene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Alcohol use disorder according to DSM 5

          -  Borderline personality disorder according to DSM 5

          -  CGI-BPD &gt; 3

          -  Female have to use contraception

        Exclusion Criteria:

          -  Other axis I disorders

          -  Severe organic disorder

          -  Pregnancy or breastfeeding

          -  Allergy to Nalmefene

          -  Subjects with Opioids use disorder or in treatment with opioid agonists
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan C Pascual, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan C Pascual, MD PhD</last_name>
    <phone>0034 93 553 78 40</phone>
    <email>jpascual@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan C Pascual, Md PhD</last_name>
      <phone>0034 93 553 78 40</phone>
      <email>jpascual@santpau.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>April 22, 2016</last_update_submitted>
  <last_update_submitted_qc>April 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nalmefene</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

